Efficacy of camrelizumab and chemotherapy plus apatinib in recurrent or advanced head and neck squamous cell carcinoma
Objective To observe the efficacy and safety of camrelizumab and chemotherapy plus apatinib in the salvageable treat-ment of recurrent or advanced head and neck squamous cell carcinoma(HNSCC).Methods Eight patients with recurrent or advanced HNSCC admitted to the Department of Stomatology of Xuzhou Central Hospital from March 2020 to November 2021 were retrospective-ly analyzed.After two cycles of treatment with camrelizumab and chemotherapy,camrelizumab and apatinib were used as maintenance treatment after tumor shrinkage.The main observation indexes were disease control rate(DCR)and objective remission rate(ORR),and the secondary observation indexes were overall survival time(OS),progression free survival time(PFS)and incidence of adverse reac-tions.Results Among 8 patients with recurrent or advanced HNSCC,ORR was 62.5%(5/8)and DCR was 87.5%(7/8).The follow-up time was 1-32 months,the median OS was 18 months,the median PFS was not reached,and the incidence of adverse reactions was 100%,but the degree was mild.Conclusion Camrelizumab and chemotherapy plus apatinib has good efficacy in the treatment of re-current or advanced HNSCC patients,which can effectively control disease progression and improve patients' quality of life.
Head and neck tumorCarcinoma,squamous cellCamrelizumabApatinibImmunotherapyChemotherapy
万方数据
维普
